Drug Trial Radar · NCT05441956
TGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer (NSCLC)
Last checked: Nov 19, 2026Latest source record: May 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
198
Actual
Start
Apr 23, 2021
Primary completion
Aug 31, 2025
Study completion Oct 31, 2025
Sponsor
- Lead sponsor
- Shenzhen TargetRx Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Sun Yat-Sen University Cancer Center
- First posted
- Jul 1, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is a multi-center, single-arm, open-label, Phase I clinical trial in 3 phases: dose escalation phase, dose expansion phase and indication expansion phase, which will explore the safety, tolerability, PK and preliminary efficacy of TGRX-326 in patients with ALK-positive or ROS1-positive advanced NSCLC.
Conditions
- Non-small Cell Lung Cancer
Interventions
TGRX-326Drug
Participants are given TGRX-326 tablets orally at one of the dose levels as pre-determined.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximal tolerated dose (MTD)Time frame: At end of Cycle 1 (each cycle is 21 days) when the probability of DLT of a dose level is higher than 33%
- Recommended phase II dose (RP2D)Time frame: At completion of the dose expansion study, an average of 1 year
- Safety profile (DLT)Time frame: Collect during Cycle 1 (each cycle is 21 days)
- Safety profile (AEs/SAEs)Time frame: Through completion of the study, an average of 1.5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.